2013 Congress

Viral Hepatitis Congress 2013
Messe Frankfurt Congress Center, Frankfurt, Germany
26–28 September 2013

Scientific Programme*
Webcast
Posters
Abstracts*

* Opens in new window

Webcast

Accessing the webcast on a PC
Click the link [PC]

Recommended specifications to avoid play back issues:
Internet Explorer 7 or above
Screen resolution of 1024 x 768 or higher
Internet bandwidth of 750 kbps or higher

Accessing the webcast on a Mac
Click the link [MAC]

Recommended specifications to avoid play back issues:
Mac OS X 10.4.8 or later
Safari 2.0.4 or later
Screen resolution of 1024 x 768 or higher
Internet bandwidth of 750 kbps or higher

To view the slides from the presentations
Click the link [Slides]

All presentations open in a new window.


Thursday 26 September 2013

Opening Ceremony
Ira Jacobson (USA), Stefan Zeuzem (Germany)
[PC] [MAC]

Keynote Lectures

SWOT analysis of currently available anti-HCV therapies
Graham Foster (UK)
[PC] [MAC] [Slides]

The HCV lifecycle: a rich source of antiviral targets
Charles Rice (USA)
[PC] [MAC] [Slides]


Friday 27 September 2013

Hepatitis C Epidemiology, Screening and Diagnosis

Epidemiology: risk of transmission in various regions of the world and prevention of routes of transmission
Francesco Negro (Switzerland)
[PC] [MAC] [Slides]

Screening: saliva and blood-based screening assays
Nezam Afdhal (USA)
[PC] [MAC] [Slides]

How different are quantitative HCV RNA assays?
Christoph Sarrazin (Germany)
[PC] [MAC] [Slides]

Oral paper
Assessing the role of intra-familial transmission in the ongoing propagation of the Egyptian hepatitis C virus epidemic
Lauren Maxwell (Canada)
[PC] [MAC] [Slides]

Panel discussion and Q&A
[PC] [MAC]

The New Era of HCV Therapies: IFN-containing regimens

Peg-IFN/RBV plus second generation protease inhibitors
Michael Fried (USA)
[PC] [MAC]

Peg-IFN/RBV plus non-protease inhibitors (NS5A, nucleotides)
Christophe Hézode (France)
[PC] [MAC] [Slides]

Peg-IFN/RBV plus DAA (quad regimens)
Jordan Feld (Canada)
[PC] [MAC] [Slides]

Panel discussion and Q&A
[PC] [MAC]

The New Era of HCV Therapies: IFN-free Regimens

Nucleotide-based combination regimens
Edward Gane (New Zealand)
[PC] [MAC] [Slides]

Combination regimens without nucleotides
David Nelson (USA)
[PC] [MAC] [Slides]

Host targeting agents
Thomas Berg (Germany)
[PC] [MAC] [Slides]

Panel discussion and Q&A
[PC] [MAC]

HCV Comorbidities

Managing HIV-HCV co-infection
Jürgen Rockstroh (Germany)
[PC] [MAC] [Slides]

Treatment of HCV-associated cryoglobulinemia and B-cell lymphoma
Antonio Craxì (Italy)
[PC] [MAC] [Slides]

Treatment of patients with diabetes mellitus and/or NASH and hepatitis C
Alfredo Alberti (Italy)
[PC] [MAC] [Slides]

Vitamin D deficiency and hepatitis C
Christian Lange (Germany)
[PC] [MAC] [Slides]

Panel discussion and Q&A
[PC] [MAC]


Saturday 28 September 2013

Clinical Challenges in Hepatitis C

Interactive case study: Treatment of active drug users
Andrew Talal (USA)
[PC] [MAC] [Slides]

Interactive case study: Treatment of cirrhotic patients
Marc Bourlière (France)
[PC] [MAC] [Slides]

Interactive case study: Treatment of patients after liver transplantation
Robert Brown (USA)
[PC] [MAC] [Slides]

Hepatitis B

Reactivation of hepatitis B during/after immunosuppression or chemotherapy
Geoffrey Dusheiko (UK)
[PC] [MAC] [Slides]

Role of quantitative HBsAg testing in the treatment of hepatitis B
Patrick Marcellin (France)
[PC] [MAC]

Nuc therapy for HBV: long-term outcomes, endpoints and risks
Paul Martin (USA)
[PC] [MAC] [Slides]

What is in the pipeline for treatment of hepatitis B? (IFN-lambda, TLR-agonists, entry inhibitors etc)
Harry Janssen (Canada)
[PC] [MAC] [Slides]

Panel discussion and Q&A
[PC] [MAC]

Hepatitis D and E

How to diagnose and treat HDV
Michael Manns (Germany)
[PC] [MAC]

Hepatitis E – are serologic tests good enough and reliable?
Heiner Wedemeyer (Germany)
[PC] [MAC] [Slides]

Chronic hepatitis E in immunocompromised patients
Stanlislas Pol (France)
[PC] [MAC] [Slides]

Panel discussion and Q&A
[PC] [MAC]

Hepatocellular carcinoma (HCC)

Approach to small HCC: ablation vs TACE vs resection
Massimo Colombo (Italy)
[PC] [MAC]

Sorafenib as an adjunct to ablation or embolization
Peter Galle (Germany)
[PC] [MAC] [Slides]

Transplantation for HCC
Pierre-Alain Clavien (Switzerland)
[PC] [MAC] [Slides]

Panel discussion and Q&A
[PC] [MAC]

Closing remarks
Ira Jacobson (USA), Stefan Zeuzem (Germany)
[PC] [MAC]

Posters

Poster presentations are available as interactive books, these are separated into topics.

  • Click the link [BOOK] for the interactive book, with turning pages (requires Adobe Flash Player).
  • Click the link [PDF] for the downloadable PDF.

Hepatitis C Virus
– Diagnosis: P1–P2
– Natural history and epidemiology: O114, O115, P3–P6A
– [BOOK] [PDF]

Hepatitis C Virus
– Treatment and late-stage clinical trials (Phase IIb, Phase III and Phase IV): P7
– Practical management strategies: P8
– Treatment monitoring and predictors of therapeutic response: P9–P17
– [BOOK] [PDF]

Hepatitis C Virus
– Preclinical and early clinical development (Phase I and Phase IIa): P18
– Other: P19–P22
– [BOOK] [PDF]

Hepatitis B Virus
– Diagnosis and monitoring: P24–P27
– Natural history and epidemiology: P28–P31
– [BOOK] [PDF]

Hepatitis B Virus
– Practical management strategies: P32
– Other: O225, P34–P38
– [BOOK] [PDF]

Other
– HIV Co-infection and Viral Hepatitis: P40–P41
– Viral Hepatitis A, D and E: P42–P47
– [BOOK] [PDF]